Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.

Barak PertzovAvraham UntermanOsnat ShtraichmanDorit ShitenbergDror RosengartenMordechai Reuven Kramer

Published in: The Journal of asthma : official journal of the Association for the Care of Asthma (2019)

Treatment with mepolizumab was well tolerated and significantly lowered the exacerbation rate and OCS dependence in a real-world cohort of severe eosinophilic asthma patients. Response to therapy was within six months and treatment effect was sustained over time.

Keyphrases

chronic obstructive pulmonary disease
lung function
ejection fraction
early onset
newly diagnosed
stem cells
allergic rhinitis